FDA Taking Another Look At Safety of Anemia Drugs
A Food and Drug Administration advisory panel will review the appropriate doses of certain anemia drugs, which have been linked to increased risks of heart attacks, blood clots, and stroke. Amgen Inc.’s Aranesp and Epogen and Johnson & Johnson’s Procrit are among the drugs set to face renewed FDA scrutiny after studies showed high amounts of the drugs can be harmful. The FDA’s intention to convene an advisory panel meeting was announced today in a commentary published in the New …
Continue →Aranesp, Other Anemia Drugs Linked to Increased Blood Clots in Cancer Patients
Using certain drugs to reduce the risks of anemia in cancer patients more than doubles the chances of developing potentially fatal blood clots in the lungs and legs, a new study finds.
Continue →Anemia Drug Aranesp Linked to Increased Risks of Heart Attack, Stroke
The Amgen Inc. anemia drug Aranesp may put users at greater risk of potentially deadly heart attack, stroke, and other circulatory problems. Also, Aranesp can shorten the survival times for people battling breast cancer and other cancers.
Continue →
facebook
rss
twitter